Form 4: UNITED THERAPEUTICS Executive Sells Shares
Insider Transaction (Form 4)
Paul A Mahon, EVP & GENERAL COUNSEL of UNITED THERAPEUTICS Corp, sold 8,300 shares of common stock on October 15, 2026.
Summary
- Option exercise/conversion: acquired 8,300 Common Stock at $146.03 ($1,212,049) on October 15, 2026; holds 53,472 after (Direct).
- Open-market sale: disposed of 268 Common Stock at $541.64 ($145,160) on October 15, 2026; holds 53,204 after (Direct).
- Open-market sale: disposed of 1,924 Common Stock at $542.49 ($1,043,753) on October 15, 2026; holds 51,280 after (Direct).
- Open-market sale: disposed of 1,983 Common Stock at $543.56 ($1,077,871) on October 15, 2026; holds 49,297 after (Direct).
- Open-market sale: disposed of 791 Common Stock at $544.85 ($430,975) on October 15, 2026; holds 48,506 after (Direct).
- Open-market sale: disposed of 2,615 Common Stock at $545.69 ($1,426,972) on October 15, 2026; holds 45,891 after (Direct).
- Open-market sale: disposed of 719 Common Stock at $546.56 ($392,977) on October 15, 2026; holds 45,172 after (Direct).
- Option exercise/conversion: disposed of 8,300 Stock Option on October 15, 2026; holds 30,940 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,517,709 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Paul A Mahon — Officer (EVP & GENERAL COUNSEL)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-15 | Option exercise/conversion | Common Stock | 8,300 | $146 | $1.2M | 53,472 |
| 2026-10-15 | Open-market sale | Common Stock | 268 | $542 | $145.2K | 53,204 |
| 2026-10-15 | Open-market sale | Common Stock | 1,924 | $542 | $1.0M | 51,280 |
| 2026-10-15 | Open-market sale | Common Stock | 1,983 | $544 | $1.1M | 49,297 |
| 2026-10-15 | Open-market sale | Common Stock | 791 | $545 | $431.0K | 48,506 |
| 2026-10-15 | Open-market sale | Common Stock | 2,615 | $546 | $1.4M | 45,891 |
| 2026-10-15 | Open-market sale | Common Stock | 719 | $547 | $393.0K | 45,172 |
| 2026-10-15 | Option exercise/conversion | Stock Option | 8,300 | — | — | 30,940 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-15 | Option exercise/conversion (8,300 shares) |
| 2026-10-15 | Open-market sale (268 shares) |
| 2026-10-15 | Open-market sale (1,924 shares) |
| 2026-10-15 | Open-market sale (1,983 shares) |
| 2026-10-15 | Open-market sale (791 shares) |
| 2026-10-15 | Open-market sale (2,615 shares) |
| 2026-10-15 | Open-market sale (719 shares) |
| 2026-10-15 | Option exercise/conversion (8,300 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Paul A Mahon
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.